Nivolumab plus relatlimab plus chemo vs nivolumab plus chemo in NSCLC
The authors reported that the primary endpoint of objective response rate was not met (51.3% versus 45.0%). In the PD-L1 ≥1% nonsquamous subgroup, a trend toward improved clinical benefit was seen (ORR 58.0% versus 39.6%; PFS HR 0.68).
Primary source
PubMed record of a Phase III journal article, October 23, 2026
Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study.
Machine-summarized from the source above; not independently reported. How we use automation